Friday Satellite Symposia-American Society of Hematology

Disclosures

The speakers of each symposium have been asked to disclose any relationships that could be perceived as a conflict of interest. Disclosures are listed alphabetically by symposium supporter.

Allos Therapeutics, Inc.
Amgen Oncology
Bristol-Myers Squibb Company
Celgene Corporation
Cephalon Oncology
ChemGenex Pharmaceuticals
Eisai, Inc.
Genentech, Inc.
Genzyme Corporation
GlaxoSmithKline
Hospira, Inc.
International Myeloma Foundation
Leukemia and Lymphoma Society
Merck and Co., Inc.
MGI Pharma, Inc.
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc., and Ortho Biotech
Miltenyi Biotec GmbH
Multiple Myeloma Research Foundation
Myelodysplastic Syndromes Foundation, Inc.
National Marrow Donor Program
Novartis
Ortho-McNeil Janssen Scientific Affairs, LLC

Allos Therapeutics, Inc.

T-Cell and B-Cell Non-Hodgkin Lymphoma Revisited: Therapeutic Paradigms and Advances

Eric Hsi, MD: paid consultant/advisory board for Allos Therapeutics, Inc.
Randy Gascoyne, MD: research funding from Roche Canada and Biogen Idec; paid consultant/advisory board for Genentech, Inc., Genitope Corporation, Johnson and Johnson, Eli Lilly and Company, and Seattle Genetics.
David Straus, MD: research funding from Merck and Co., Inc., and Ortho Biotech Products, L.P.; paid consultant/advisory board for Amgen, Eisai Medical Research, Inc., Merck and Co., Inc., Novartis Pharmaceuticals Corporation, and Therakos, Inc.; speakers bureau for Merck and Co., Inc.

Amgen Oncology

Critical Advances in the Management of Immune Thrombocytopenic Purpura

Andrew Provan, MD: research funding from Amgen, Baxter International, Inc., and GlaxoSmithKline; paid consultant/advisory board for Amgen and GlaxoSmithKline; speakers bureau for Amgen and Baxter International, Inc.; stock investment holdings with GlaxoSmithKline.
Mansoor Saleh, MD: speakers bureau for Bristol-Myers Squibb Company, GlaxoSmithKline, ImClone Systems Incorporated, and Novartis Pharmaceuticals Corporation; research funding from Bristol-Myers Squibb Company, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation.
Morey Blinder, MD: speakers bureau for GlaxoSmithKline.
Keith McCrae, MD: paid consultant/advisory board for Baxter and GlaxoSmithKline; speakers bureau for GlaxoSmithKline.

Bristol-Myers Squibb Company

The Real Deal With CML: Case- and Dialogue-Based Education Designed to Facilitate Integration of New Agents and Guidelines Into Clinical Practice

Neil Shah, MD, PhD: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, and Exelixis.
John M. Goldman, DM: Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation.
Timothy Hughes, MD: Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation.
Moshe Talpaz, MD: Novartis Pharmaceuticals Corporation.
Michael Mauro, MD: Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation.

Celgene Corporation

Bone Marrow Failure Syndromes: Optimizing Outcomes Worldwide Through Disease Understanding

Mikkael Sekeres, MD: Celgene and Pharmion.
Aristoteles A.N. Giagoundis, MD: Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation.
James G. Herman, MD: OncoMethylome Sciences and Pharmion.
Pierre Fenaux, MD: Pharmion, Celgene, Amgen, Janssen-Cilag, Novartis, Roche, and Cephalon.
Christin Engelhardt: indicated no conflicts of interest.
Louis Degennaro, PhD: indicated no conflicts of interest.

Cephalon Oncology

Management of Hematologic Malignancies in the Aging Population: Biology, Molecular Prognostic Markers, and Novel Treatment Strategies

Bruce D. Cheson, MD: consultant for Abbott, Astellas, and Celgene.
Harry Erba, MD, PhD: speaker for Celgene, Genzyme, Novartis, Pharmion, and Wyeth; principal investigator for Cell Therapeutics, Cephalon, Kanisa, Xanthus.
Kanti Rai, MD: consultant for Genta; speaker for Bayer and Genentech.
Bart Barlogie, MD: speaker for the University of Arkansas Medical Sciences Myeloma Institute for Research and Therapy.
Mathias Rummel, MD, PhD: indicated no conflicts of interest.

ChemGenex Pharmaceuticals

Overcoming Resistance in CML: Contemporary Disease Monitoring Practices

Jane F. Apperley, MD: Off-label/investigational-use drugs will be included in the presentation: unlicensed tyrosine kinase inhibitors, e.g. bosutinib and homoharringtonine.
Alfonso Quintas-Cardama, MD: indicated no conflicts of interest.
Andreas Hochhaus, MD: Bristol-Myers Squibb Company, Innovive Pharmaceuticals, Merck and Company, Inc., Novartis Pharmaceuticals, Premier Research, and Wyeth Pharmaceuticals.
Franck Emmanuel Nicolini, MD, PhD: indicated no conflicts of interest.
Luke Akard, MD: indicated no conflicts of interest.

Eisai, Inc.

Thromboembolism in Cancer Patients: A Cogent Approach to Risk Assessment, Prevention, and Treatment

Gary H. Lyman, MD: grant/research support from Amgen and Genomic Health; speakers bureau for Amgen and Genomic Health.
Alok A. Khorana, MD: grant/research support from Bristol-Myers Squibb; speakers bureau for Sanofi-Aventis, Eisai, Genentech, and Eli Lilly.
Michael M. Millenson, MD: speakers bureau for GlaxoSmithKline; advisory board for Celgene; wife is an employee of Sanofi-Aventis (as a global safety officer).

Genentech, Inc.

Second Opinion: An Interactive Case-Based Discussion on the Management of Non-Hodgkin Lymphomas

Ian W. Flinn, MD, PhD: advisory committee for Biogen Idec and Celgene Corporation; speakers bureau for Genentech BioOncology.
Stephanie A. Gregory, MD: paid research for Amgen, Inc., Biogen Idec., Boehringer Ingelheim Gmbl-I, Celgene Corporation, Genentech BioOncology, Genmab, GlaxoSmithKline, Gloucester Pharmaceuticals, Millennium Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., and Wyeth; speakers bureau for Cephalon, Inc., Genentech BioOncology, and GlaxoSmithKline.
John P. Leonard, MD: advisory committee for Celgene Corporation, Cephalon, Inc., Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pharmion Corporation, and Wyeth; consulting agreements with Biogen Idec, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pharmion Corporation, and Wyeth; speakers bureau for GlaxoSmithKline and Millennium Pharmaceuticals, Inc.
David G. Maloney, MD, PhD: Advisory Committee: Biogen Idec, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Pharmion Corporation, Roche Laboratories, Inc.
Mitchell R. Smith, MD, PhD: Celgene Corporation; Genentech BioOncology; Paid Research: Pfizer, Inc, Wyeth; Speakers Bureau: Biogen Idec, Cephalon Inc. Genentech BioOncology
Andrew D. Zelenetz, MD, PhD: Consulting Agreements: Abbott Laboratories, Cell Therapeutics Inc., Cephalon Inc, Favrille Inc, Genentech BioOncology, MGI Pharma Inc; Paid Research: Amgen Inc, Genentech BioOncoogy, GlaxoSmithKline

Genzyme Corporation

High-Risk AML: Molecular Biology, Treatment, Future Directions

Hagop M. Kantarjian, MD: grants/research support from Novartis, Bristol-Myers Squibb, and MGI Pharma.
Hartmut Döhner, MD: indicated no conflicts of interest.
Jerald P. Radich, MD: indicated no conflicts of interest.
Wendy Stock, MD: grants/research support from Berlex and Genzyme; consultant fees from Enzon and Novartis.
Richard Stone, MD: grants/research support from Novartis; consultant fees from Genzyme; speakers bureau for Celgene Corporation and Pharmion.
Gail Roboz, MD: grants/research support from Cephalon; consultant fees and honoraria from Celgene and Cephalon.
Daniel Weisdorf, MD: grants/research support from Amgen, DOR BioPharma, Genzyrne, Ligand, Merck, Miltenyi Biotec, and Roche; consultant fees from DOR BioPharma.

GlaxoSmithKline

The Changing Face of Thrombocytopenia Management: A Focus on Improving Patient Outcomes

James Bussel, MD: grants/research support from Pharmion, Celgene, Amgen, Janssen-Cilag, Novartis, Roche, and Cephalon; stockholder with GlaxoSmithKline and Amgen; honoraria from Baxter.
Douglas Cines, MD: consultant for GlaxoSmithKline, Amgen, Symphogen, Baxter, Ligand, Rigel, and Genzyme.
Kenneth Bauer, MD: honoraria from GlaxoSmithKline (fondaparinux) and Sanofi-Aventis (enoxaparin).

Hospira, Inc.

50 Years of Enormous Progress in Hairy Cell Leukemia: A Celebration of Clinical Research With Remaining Unanswered Questions

John Cawley, MD, PhD: financial support from Leukemia Research Foundation.
Alan Saven, MD: indicated no conflicts of interest.
Francesco Lauria, MD: grants/research support from Novartis, Genentech, and Amgen; honoraria from Novartis and Bristol-Myers Squibb; editorial board involvement with Clinical Leukemia.
Michael Grever, MD: indicated no conflicts of interest.
Daniel Catovsky, MD: consultant: Genzyme and Roche; Advisory Board Membership: Roche and Hospira
Deborah Thomas, MD: grants/research support: Novartis, Genentech, and Amgen; honoraria from: Novartis and Bristol-Meyer Squibb; editorial board involvement with Clinical Leukemia
Pier Luigi Zinzani, MD: indicated no conflicts of interest
Back to Top

International Myeloma Foundation

Multiple Myeloma: Finding Your Way Through the Treatment Maze – Selecting the Best Treatment in the Era of Novel Agents

Brian G.M. Durie, MD: advisory board for and research support from Celgene and Millennium.
Antonio Palumbo, MD: speaker services for Celgene, Janssen-Cilag, and Pharmion.
S. Vincent Rajkumar, MD: grant support related to research activities from Celgene Corporation.
Jesus San Miguel, MD, PhD: speaker services for Millennium, Celgene, and Pharmion.

Leukemia and Lymphoma Society

Emerging Approaches in Apoptotic and Cell Cycle Control of Hematopoietic Malignancies

Jerry Adams, PhD: financial support from Genentech and Abbott.
Selina Chen-Kiang, PhD: indicated no conflicts of interest.
Stephen Fesik, PhD: indicated no conflicts of interest.
John Reed, MD, PhD: indicated no conflicts of interest.

Merck and Co., Inc.

The Hematology Circle: Optimizing Epigenetic Therapy to Improve Outcomes

Ashraf Z. Badros, MD: indicated no conflicts of interest.
Francine M. Foss, MD: grant/research support from Merck and Co., Inc.; consultant for Gloucester Pharmaceuticals; speakers bureaus for Merck and Co., Inc., and Biogen Idec.
Elihu E. Estey, MD: indicated no conflicts of interest.
Jorge Eduardo Cortes, MD: grant/research support from Novartis, Bristol-Myers Squibb, and Wyeth. Dr. Cortes will reference unlabeled/unapproved uses of drugs during his presentation.

MGI Pharma, Inc.

Treating AML/MDS: New Solutions for a Long-Standing Problem

Jacob Rowe, MD: indicated no conflicts of interest.
Judy Karp, MD: advisory board for Actinium Pharmaceuticals, Inc., and Vion Pharmaceuticals, Inc.; Data and Safety Monitoring Board for Anza (Cerus) and Xanthus Pharmaceuticals, Inc.
Bob Löwenberg, MD: Equity ownership in Skyline Diagnostics.
Rainer Storb, MD: indicated no conflicts of interest.
Christopher Bredeson, MD: speaker and advisory board for MGI Pharma, Inc.
Gary Schiller, MD: research contract with Celgene, Genzyme Pharmaceuticals, Johnson and Johnson Pharmaceuticals, MGI Pharma, Inc., Millennium, and Vion Pharmaceuticals.
Maria Baer, MD: speaker for Celgene and MGI Pharma, Inc.

Millennium Pharmaceuticals, Inc.

Emerging Standards of Care: Bringing Advances in Myeloma Therapy Into the Real World

Sergio Giralt, MD: honoraria from Celgene, Millennium, and Novartis.
Michele Cavo, MD: consultant for Janssen-Cilag and Novartis.
Meletios A. Dimopoulos, MD: consultant for and honoraria from Ortho Biotech, Celgene, and Novartis.
Mario Boccadoro, MD: consultant for Celgene.
Jeffrey Zonder, MD: speakers bureau and honoraria from Celgene.
Shaji Kumar, MD: contracted research with Celgene, Millennium, and Bayer.
Jonathan Kaufman, MD: honoraria from Celgene and Millennium.
Hakan Kaya, MD: consultant for Millennium.
Choon-Kee Lee, MD: honoraria from Millennium.
Magda Migkou, MD: indicated no conflicts of interest.
Elena Zamagni, MD: indicated no conflicts of interest.

Millennium Pharmaceuticals, Inc., and Ortho Biotech

Clinical Crossroads: Factors Critical to Successful Patient Management in Lymphoproliferative Disorders

Andre Goy, MD: consulting fees from Genentech and Millennium Pharmaceuticals.
Anton Hagenbeek, MD, PhD: indicated no conflicts of interest.
Robert Z. Orlowski, MD, PhD: consulting fees from Celgene, Millennium Pharmaceuticals, Ortho Biotech, and Proteolix.
Steven P. Treon, MD, PhD: consulting fees from Biogen Idec, Celgene, Genentech, Millennium Pharmaceuticals, and Roche.
Amitabha Mazumder, MD: consulting fees from Celgene and Millennium Pharmaceuticals.

Miltenyi Biotec GmbH

Cellular Therapy: Stem Cell Transplantations From Matched Related and Unrelated Donors

Ralf G. Meyer, MD: indicated no conflicts of interest.
Jeffrey S. Miller, MD: consulting fees from Novo Nordisk.
Matthias Edinger, MD: consulting fees from Therakos.
Tobias Feuchtinger, MD: indicated no conflicts of interest.

Multiple Myeloma Research Foundation

Debating the Key Clinical Questions for the Management of Patients With Multiple Myeloma

Kenneth Anderson, MD: research support from Celgene and Millennium; speaker and consultant for Celgene, Millennium, and Novartis.
William Bensinger, MD: consultant for Millennium; speaker for Celgene and Millennium.
Sundar Jagannath, MD: speaker for Celgene and Ortho Biotech; advisory board for Millennium.
Sagar Lonial, MD: consultant for Celgene and Millennium.
Paul Richardson, MD: advisory board/speaker for Celgene and Millennium.

Myelodysplastic Syndromes Foundation, Inc.

Integrating New Developments in MDS Into Clinical Practice

Alan F. List, MD: indicated no conflicts of interest.
John M. Bennett, MD: indicated no conflicts of interest.
P.K. Epling-Burnett, MD: indicated no conflicts of interest.
Guillermo Garcia-Manero, MD: indicated no conflicts of interest.
Marilyn Slovak, MD: indicated no conflicts of interest.
Detlef Haase, MD: indicated no conflicts of interest.

National Marrow Donor Program

Allogeneic Transplantation: Applying New Research for Improved Outcomes

Dennis Confer, MD: indicated no conflicts of interest.
Claudio Anasetti, MD: royalty rights patent; honoraria from and advisory board for PDL BioPharma and Genzyme; honorarium from and speaker for Celgene.
Mary Horowitz, MD: indicated no conflicts of interest.
Alois Gratwohl, MD: research support from and advisory committee for Bristol-Myers Squibb and Novartis; research support from Amgen; consultant for Pfizer; research support from and consultant for Osiris.

Novartis

Solving the Challenges of Hematologic Malignancies Through Translational Science

Jonathan Licht, MD: indicated no conflicts of interest.
Owen O’Connor, MD, PhD: grant/research support from Allos, Ascenta, and Merck; grant/research support from and speakers bureau for Millennium.
H. Miles Prince, MD: advisory board and research grant from Celgene; speaker and advisory board for Novartis.
Frank Giles, MD: grant/research support from Amgen, Bristol-Myers Squibb, Clavis, Merck, Novartis, and SGX.
Ruben Mesa, MD: indicated no conflicts of interest.

Ortho-McNeil Janssen Scientific Affairs, LLC

New Perspectives, New Strategies in Venous Thromboembolic Disease

Jeffrey Weitz, MD: advisory board for Eisai, Daiichi-Sankyo, Schering- Plough, Bristol-Myers Squibb, SmithKline Beecham, Sanofi-Aventis, and Portola; consultant for AstraZeneca, The Medicines Company, Schering-Plough, Bayer, Bristol-Myers Squibb, and Merck AG.
Charles T. Esmon, PhD: advisory board for Cardiome; consultant (self and spouse) for Teva, Portola, Artison, Novartis, Schering-Plough, Crucell, Novo Nordisk, and Cardiome; intellectual property/patents (self and spouse) for Eli Lilly and Company and Baxter.
Alexander G.G. Turpie, MD: advisory board for Bayer, Johnson and Johnson, Pfizer, Scios, Bristol-Myers Squibb, Sanofi-Aventis, Astellas, and Portola; consultant for Bayer, Astellas, and Sanofi-Avenits; speakers bureau for GlaxoSmithKline.
Richard Joel Friedman, MD: advisory board for Boehringer Ingelheim; consultant for Boehringer Ingelheim and Astellas; shareholder with Bayer and Bristol-Myers Squibb; grant recipient from Boehringer Ingelheim, Takeda, Astellas, and Bristol-Myers Squibb; speakers bureau for Sanofi-Aventis. Dr. Friedman will reference the following off-label/unapproved use of drugs or devices in his presentation: rivaroxaban (Bayer); dabigatran (Boehringer Ingelheim).